Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1937]

Blinatumomab and oral TKIs for the treatment of Ph ALL

Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA

Blinatumomab and oral TKIs for the treatment of Ph ALL ( Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA )

D-ALBA update: Frontline sequential dasatinib and blinatumomab in adult Ph ALL

Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA

D-ALBA update: Frontline sequential dasatinib and blinatumomab in adult Ph ALL ( Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA )

Real world management of multiple myeloma patients

Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina

Real world management of multiple myeloma patients ( Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina )

Bosutinib versus imatinib for newly diagnosed chronic phase CML: BFOREfinal 5...

Prof Tim Brümmendorf - RWTH Aachen University, Aachen, Germany

Bosutinib versus imatinib for newly diagnosed chronic phase CML: BFOREfinal 5-year results ( Prof Tim Brümmendorf - RWTH Aachen University, Aachen, Germany )

Weekly carfilzomib and dexamethasone plus/minus cyclophosphamide for RRMM...

Dr Albert Oriol - Josep Carreras Leukaemia Research Institute, Badalona, Spain

Weekly carfilzomib and dexamethasone plus/minus cyclophosphamide for RRMM patients ( Dr Albert Oriol - Josep Carreras Leukaemia Research Institute, Badalona, Spain )

FORTE trial: Impact of minimal residual disease on multiple myeloma patients

Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy

FORTE trial: Impact of minimal residual disease on multiple myeloma patients ( Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy )

Evaluation of MRD negativity in patients with relapsed or refractory multiple...

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

$Evaluation of MRD negativity in patients with relapsed or refractory multiple myeloma treated in the CANDOR study ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )$

ZUMA-12: Axicabtagene ciloleucel for high-risk large B cell lymphoma

Prof Sattva Neelapu - MD Anderson Cancer Center, Houston, USA

ZUMA-12: Axicabtagene ciloleucel for high-risk large B cell lymphoma ( Prof Sattva Neelapu - MD Anderson Cancer Center, Houston, USA )

Neurocognitive impairment in long-term survivors of childhood Hodgkin lymphoma

Dr Annalynn M Williams - St. Jude Children's Research Hospital, Memphis, USA

Neurocognitive impairment in long-term survivors of childhood Hodgkin lymphoma ( Dr Annalynn M Williams - St. Jude Children's Research Hospital, Memphis, USA )

Venetoclax combined with AML induction/consolidation therapy with FLAG-IDA in...

Dr Curtis Lachowiez - University of Texas MD Anderson Cancer Center, USA

Venetoclax combined with AML induction/consolidation therapy with FLAG-IDA in newly diagnosed or R/R AML ( Dr Curtis Lachowiez - University of Texas MD Anderson Cancer Center, USA )

Hyper-CVAD and sequential blinatumomab in adults with newly diagnosed...

Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA

Hyper-CVAD and sequential blinatumomab in adults with newly diagnosed Philadelphia chromosome-negative B-cell ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )

Ponatinib, venetoclax and dexamethasone for patients with relapsed or...

Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA

$Ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory Philadelphia chromosome-positive ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )$

More from ecancer